ETR:MDG1 - MediGene Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started €8.82 -0.06 (-0.68 %) (As of 02/22/2019 04:00 PM ET)Previous Close€8.89Today's Range€8.82 - €9.0552-Week Range€8.53 - €19.27Volume42,355 shsAverage Volume306,207 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and research collaboration agreements with RXi Pharmaceuticals Corporation. The company was founded in 1994 and is headquartered in Munich, Germany. Receive MDG1 News and Ratings via Email Sign-up to receive the latest news and ratings for MDG1 and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange ETR Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolETR:MDG1 Previous Symbol CUSIPN/A CIKN/A Webwww.medigene.de Phone+49-89-2000330Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees99 Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable MediGene (ETR:MDG1) Frequently Asked Questions What is MediGene's stock symbol? MediGene trades on the ETR under the ticker symbol "MDG1." What price target have analysts set for MDG1? 3 Wall Street analysts have issued 12-month price objectives for MediGene's shares. Their predictions range from €10.80 to €17.00. On average, they anticipate MediGene's share price to reach €13.93 in the next year. This suggests a possible upside of 58.0% from the stock's current price. View Analyst Price Targets for MediGene. What is the consensus analysts' recommendation for MediGene? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediGene in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MediGene. Has MediGene been receiving favorable news coverage? Headlines about MDG1 stock have trended positive this week, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. MediGene earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of MediGene's key competitors? Some companies that are related to MediGene include 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), AorTech International (AOR), Arix Bioscience (ARIX), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Biocure Technology (CURE), Biotest (BIO), Bioventix (BVXP) and BTG (BTG). What other stocks do shareholders of MediGene own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediGene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Cerecor (CERC), AcelRx Pharmaceuticals (ACRX), Pieris Pharmaceuticals (PIRS), New York REIT (NYRT), MOTIF BIO PLC/S (MTFB), NuCana (NCNA), Viewray (VRAY) and Corbus Pharmaceuticals (CRBP). Who are MediGene's key executives? MediGene's management team includes the folowing people: Prof. Horst Domdey, Co-Founder & Chairman of the Supervisory Board (Age 68)Prof. Dolores J. Schendel, CEO, Chief Scientific Officer & Member of Exec. Management BoardDr. Thomas Taapken, CFO & Member of Exec. Management Board (Age 54)Prof. Ernst-Ludwig Winnacker, Co-Founder & Chairman Scientific Advisory Board (Age 78)Dr. Kai Pinkernell, Chief Medical Officer, Chief Devel. Officer & Member of Exec. Management Board What is MediGene's stock price today? One share of MDG1 stock can currently be purchased for approximately €8.82. What is MediGene's official website? The official website for MediGene is https://www.medigene.de/. How can I contact MediGene? MediGene's mailing address is Lochhamer Strasse 11, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-2000330. MarketBeat Community Rating for MediGene (ETR MDG1)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 126 (Vote Outperform)Underperform Votes: 122 (Vote Underperform)Total Votes: 248MarketBeat's community ratings are surveys of what our community members think about MediGene and other stocks. Vote "Outperform" if you believe MDG1 will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDG1 will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2019 by MarketBeat.com StaffFeatured Article: Why is the price-sales ratio important?